OrbusNeich Medical today said it won market approval in Japan for its Combo Plus coronary stent.
The Combo Plus stent is designed to address the risk of stent thrombosis associated with delayed healing in conventional drug-eluting stents. The Combo Plus DES uses endothelial progenitor cell capture technology and abluminal sirolimus drug elution delivered from a biodegradable matrix polymer that fully dissipates within 90 days, according to the Hong Kong-based company.
Get the full story on our sister site, Drug Delivery Business.